Core Viewpoint - The recent strategic transformation of Huajian Medical aims to evolve from a traditional medical testing service provider to a "global innovative drug asset digital trading platform operator," attracting significant market and investor attention [1][2]. Group 1: Company Strategy and Innovations - Huajian Medical is exploring the RWA exchange ecosystem, providing a new development model for the medical industry, addressing core pain points in innovative drug financing and market access [4]. - The RWA exchange ecosystem aims to leverage blockchain technology to ensure asset rights, pricing, and cross-border transactions, facilitating a more efficient pathway for innovative drugs to reach global investors [4][8]. - The collaboration with BGI to establish an innovative drug intellectual property tokenization fund is part of Huajian Medical's strategy to create a three-in-one model of "innovative drug assets + RWA exchange + stablecoin" [8]. Group 2: Stakeholder Relationships - Xinhua Medical holds a 27.29% stake in Huajian Medical, indicating a strategic partnership that could yield collaborative opportunities in the future [1][5]. - Xinhua Medical's responses on investor platforms reflect a rational and cautious approach towards Huajian Medical's developments, while also hinting at potential strategic synergies [5][10]. - The relationship allows Xinhua Medical to benefit from Huajian Medical's profit growth without directly engaging in compliance risks associated with RWA and stablecoin [10][12]. Group 3: Market Potential and Future Outlook - The market potential for tokenized real assets is projected to exceed $18 trillion by 2033, with a compound annual growth rate of 53% since 2025, highlighting the significant growth opportunities in the innovative drug and medical sectors [10]. - Huajian Medical's innovative approach positions it as a unique investment opportunity, with its valuation supported by the scarcity premium and early-stage growth potential [10][12].